QCG
PTGX icon

Quadrant Capital Group’s Protagonist Therapeutics PTGX Stock Holding History

Quadrant Capital Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,429
Closed -$151K – 2241
2026
Q1 		$151K Sell
1,429
-38
-3% -$3.37K ﹤0.01% 1352
2025
Q4 		$128K Buy
1,467
+115
+9% +$9.41K ﹤0.01% 1428
2025
Q3 		$89.8K Buy
+1,352
New +$76.8K ﹤0.01% 1498
2025
Q2 		– Sell
-3,278
Closed -$159K – 2284
2025
Q1 		$159K Buy
+3,278
New +$137K 0.01% 1394
2024
Q4 		– Sell
-140
Closed -$6.3K – 2781
2024
Q3 		$6.3K Buy
+140
New +$5.66K ﹤0.01% 2267

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Quadrant Capital Group's PTGX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 1,429 shares — an estimated $151K sold.

Quadrant Capital Group first reported a position in PTGX in Q3 2024 and held it in 5 quarters. The position peaked at $159K in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,429 Protagonist Therapeutics shares in Q2 2026, an estimated $151K.
  • Quadrant Capital Group first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 5 quarters.
  • Quadrant Capital Group's Protagonist Therapeutics position peaked at $159K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.